Cytogen Corp. shares jumped $3 on Wednesday after itsEuropean marketing partner announced that OncoScint CR103,a monoclonal antibody-based imaging agent for colorectalcancer, has received marketing approval in Spain. OncoScint isnow approved in six European countries.
EuroCetus B.V., based in Amsterdam, the Netherlands, is theexclusive marketing partner in Europe for the OncoScintproduct line developed by the Princeton, N.J., company(NASDAQ:CYTO).
EuroCetus is a wholly owned subsidiary of Cetus Oncology, aU.S.-based unit of Chiron Corp. (NASDAQ:CHIR) of Emeryville,Calif.
Cytogen closed Wednesday at $22.63. Chiron gained $2.50 to$67.75.
On Tuesday, Cytogen said it has started Phase I trials of itsOncoTc breast cancer imaging agent, a fragment of amonoclonal antibody that seeks and binds to breast tumor cells.The fragment is linked to technetium-99m radioisotope.
(c) 1997 American Health Consultants. All rights reserved.